Company profile
Mission Therapeutics Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
Mission Therapeutics Limited is a UK company with status active founded in 2011 based in East of England.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
CS01 | Transaction MzUzMDA1NDkwMWFkaXF6a2N4
Published 02 Jul 2026 10:56
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0NDkzMDE3MmFkaXF6a2N4
Published 26 Nov 2024 01:25
Company registered at Companies House
1 Oct 2015 to 30 Sep 2017
MISSION Therapeutics, a UK-based SME is a world-leading expert in deubiquitylating enzyme (DUB) drug discovery, with a number of projects in lead optimisation. Through counter-screening our ongoing projects, we identified a small molecule inhibtiors of a DUB drug target with potential to be developed for treating soft tissue sarcomas and other cancers wit...
1 Aug 2014 to 31 Jul 2015
Through work funded by the TSB, MISSION Therapeutics identified SENP enzymes as new therapeutic targets for treating drug-resistant ovarian cancer. For drug discovery, SENPs pose a distinct challenge as they require specific substrates and assays and they are not well studied in terms of their biological role(s). For these reasons, SENPS are currently con...
1 Apr 2013 to 31 Mar 2014
Novel therapies tailored for treatment of platinum-resistant ovarian cancer is an area of clear unmet need. Ovarian cancer is responsible for more deaths per year than any other cancer of the female reproductive system and developing drug resistance remains the main limitation of current chemotherapies. We propose an innovative approach to identifying nov...
